A study to demonstrate comparable safety, efficacy, and pharmacokinetics (PK) of
alglucosidase alfa manufactured at the 160 litre (L) and 4000 L scales in participants who
had been diagnosed with infantile-onset Pompe disease. Participants were treated with
alglucosidase alfa 160 L scale product in the United States (US) and 4000 L scale product in
the regions outside the US.